Development of Federally Mandated Risk Evaluation and Mitigation Strategies (REMS) for Transmucosal Immediate-Release Fentanyl Products

Lignende værker

• Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products
  af: Rollman, Jeffrey Eric, et al.
  Udgivet: (2019)
• Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing
  af: Fleischman, William, et al.
  Udgivet: (2019)
• Safety and Efficacy of Oral Transmucosal Fentanyl Citrate Compared to Morphine Sulphate Immediate Release Tablet in Management of Breakthrough Cancer Pain
  af: Bhatnagar, Sushma, et al.
  Udgivet: (2014)
• The changing landscape of opioid prescribing: long-acting and extended-release opioid class-wide Risk Evaluation and Mitigation Strategy
  af: Gudin, Jeffrey A
  Udgivet: (2012)
• Characteristics of Analgesic Patch Formulations
  af: Nalamachu, Srinivas, et al.
  Udgivet: (2020)